RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.38 Million CAD | -624.13% |
| 2022 | -191.43 Thousand CAD | 93.96% |
| 2021 | -3.17 Million CAD | -177.17% |
| 2020 | -1.14 Million CAD | 60.3% |
| 2019 | -2.88 Million CAD | -5.24% |
| 2018 | -2.73 Million CAD | 54.28% |
| 2017 | -5.99 Million CAD | -39.75% |
| 2016 | -4.28 Million CAD | 15.04% |
| 2015 | -5.04 Million CAD | 3.14% |
| 2014 | -5.21 Million CAD | -1459.66% |
| 2013 | 383.22 Thousand CAD | 108.57% |
| 2012 | -4.47 Million CAD | -21.12% |
| 2011 | -3.69 Million CAD | -53.65% |
| 2010 | -2.4 Million CAD | -1617.11% |
| 2009 | -140 Thousand CAD | -3.01% |
| 2008 | -135.91 Thousand CAD | 77.55% |
| 2007 | -605.38 Thousand CAD | -170.4% |
| 2006 | -223.88 Thousand CAD | 37.37% |
| 2005 | -357.47 Thousand CAD | 67.28% |
| 2004 | -1.09 Million CAD | -976.12% |
| 2003 | -101.5 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -126.23 Thousand CAD | 58.28% |
| 2024 Q2 | -65.56 Thousand CAD | 48.06% |
| 2023 Q3 | -671.15 Thousand CAD | -32.52% |
| 2023 Q1 | -727.19 Thousand CAD | -127.63% |
| 2023 FY | -1.38 Million CAD | -624.13% |
| 2023 Q2 | -506.46 Thousand CAD | 30.35% |
| 2023 Q4 | -302.58 Thousand CAD | 54.92% |
| 2022 Q2 | -1.03 Million CAD | -35.14% |
| 2022 FY | -191.43 Thousand CAD | 93.96% |
| 2022 Q1 | -765.1 Thousand CAD | 8.15% |
| 2022 Q4 | 2.63 Million CAD | 356.91% |
| 2022 Q3 | -1.02 Million CAD | 0.91% |
| 2021 Q1 | -479.86 Thousand CAD | -97.11% |
| 2021 Q3 | -545.82 Thousand CAD | 31.91% |
| 2021 Q4 | -832.99 Thousand CAD | -52.61% |
| 2021 Q2 | -801.56 Thousand CAD | -67.04% |
| 2021 FY | -3.17 Million CAD | -177.17% |
| 2020 Q4 | -243.44 Thousand CAD | 53.27% |
| 2020 Q2 | -275.44 Thousand CAD | 17.51% |
| 2020 Q1 | -333.9 Thousand CAD | 44.12% |
| 2020 FY | -1.14 Million CAD | 60.3% |
| 2020 Q3 | -520.97 Thousand CAD | -89.14% |
| 2019 Q3 | -561.58 Thousand CAD | 39.84% |
| 2019 Q2 | -933.47 Thousand CAD | -0.89% |
| 2019 FY | -2.88 Million CAD | -5.24% |
| 2019 Q4 | -597.58 Thousand CAD | -6.41% |
| 2019 Q1 | -925.2 Thousand CAD | -3.4% |
| 2018 FY | -2.73 Million CAD | 54.28% |
| 2018 Q2 | -590.34 Thousand CAD | -21.39% |
| 2018 Q1 | -486.32 Thousand CAD | 16.88% |
| 2018 Q4 | -894.75 Thousand CAD | -16.52% |
| 2018 Q3 | -767.87 Thousand CAD | -30.07% |
| 2017 Q4 | -585.1 Thousand CAD | 51.82% |
| 2017 Q3 | -1.21 Million CAD | 51.28% |
| 2017 Q2 | -2.49 Million CAD | -46.68% |
| 2017 Q1 | -1.69 Million CAD | 3.86% |
| 2017 FY | -5.99 Million CAD | -39.75% |
| 2016 Q2 | -786.62 Thousand CAD | 28.13% |
| 2016 Q4 | -1.76 Million CAD | -176.66% |
| 2016 FY | -4.28 Million CAD | 15.04% |
| 2016 Q1 | -1.09 Million CAD | 15.73% |
| 2016 Q3 | -638.92 Thousand CAD | 18.78% |
| 2015 FY | -5.04 Million CAD | 3.14% |
| 2015 Q4 | -1.29 Million CAD | -10.22% |
| 2015 Q3 | -1.17 Million CAD | 13.74% |
| 2015 Q2 | -1.36 Million CAD | -13.47% |
| 2015 Q1 | -1.2 Million CAD | 13.45% |
| 2014 Q2 | -1.37 Million CAD | -16.16% |
| 2014 Q3 | -1.26 Million CAD | 8.17% |
| 2014 Q1 | -1.18 Million CAD | -3.51% |
| 2014 FY | -5.21 Million CAD | -1459.66% |
| 2014 Q4 | -1.39 Million CAD | -10.21% |
| 2013 FY | 383.22 Thousand CAD | 108.57% |
| 2013 Q4 | -1.14 Million CAD | -135.35% |
| 2013 Q2 | -1.01 Million CAD | -45.1% |
| 2013 Q3 | 3.23 Million CAD | 419.94% |
| 2013 Q1 | -696.49 Thousand CAD | 25.14% |
| 2012 Q1 | -749.38 Thousand CAD | 4.96% |
| 2012 Q2 | -1.74 Million CAD | -132.33% |
| 2012 Q4 | -930.34 Thousand CAD | -12.55% |
| 2012 Q3 | -826.6 Thousand CAD | 52.52% |
| 2012 FY | -4.47 Million CAD | -21.12% |
| 2011 Q3 | -890.77 Thousand CAD | 20.32% |
| 2011 Q1 | -897.29 Thousand CAD | 60.91% |
| 2011 Q2 | -1.11 Million CAD | -24.59% |
| 2011 Q4 | -788.51 Thousand CAD | 11.48% |
| 2011 FY | -3.69 Million CAD | -53.65% |
| 2010 Q3 | -54.82 Thousand CAD | -43.83% |
| 2010 Q2 | -38.11 Thousand CAD | -138.42% |
| 2010 Q1 | -15.98 Thousand CAD | 59.1% |
| 2010 Q4 | -2.29 Million CAD | -4086.38% |
| 2010 FY | -2.4 Million CAD | -1617.11% |
| 2009 Q3 | -17.49 Thousand CAD | 56.35% |
| 2009 Q4 | -39.09 Thousand CAD | -123.42% |
| 2009 Q2 | -40.08 Thousand CAD | 7.48% |
| 2009 Q1 | -43.33 Thousand CAD | -29.17% |
| 2009 FY | -140 Thousand CAD | -3.01% |
| 2008 Q1 | -39.04 Thousand CAD | 31.34% |
| 2008 Q4 | -33.54 Thousand CAD | 12.63% |
| 2008 Q3 | -38.39 Thousand CAD | -51.72% |
| 2008 Q2 | -25.3 Thousand CAD | 35.19% |
| 2008 FY | -135.91 Thousand CAD | 77.55% |
| 2007 Q3 | -133.25 Thousand CAD | -85.03% |
| 2007 Q1 | -343.99 Thousand CAD | -4989.93% |
| 2007 FY | -605.38 Thousand CAD | -170.4% |
| 2007 Q4 | -56.87 Thousand CAD | 57.32% |
| 2007 Q2 | -72.01 Thousand CAD | 79.06% |
| 2006 Q3 | -90.84 Thousand CAD | 3.95% |
| 2006 Q1 | -45.45 Thousand CAD | -371.05% |
| 2006 FY | -223.88 Thousand CAD | 37.37% |
| 2006 Q4 | 7034.78 CAD | 107.74% |
| 2006 Q2 | -94.57 Thousand CAD | -108.09% |
| 2005 Q3 | -132.85 Thousand CAD | -47.33% |
| 2005 FY | -357.47 Thousand CAD | 67.28% |
| 2005 Q2 | -90.17 Thousand CAD | 27.55% |
| 2005 Q1 | -124.45 Thousand CAD | 79.32% |
| 2005 Q4 | -9648.92 CAD | 92.74% |
| 2004 Q1 | -19.27 Thousand CAD | 0.0% |
| 2004 Q2 | -130.57 Thousand CAD | -577.46% |
| 2004 Q4 | -601.82 Thousand CAD | -99.17% |
| 2004 FY | -1.09 Million CAD | -976.12% |
| 2004 Q3 | -302.16 Thousand CAD | -131.42% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | -101.5 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.069% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 128.206% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.172% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.233% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.694% |
| Mesoblast Limited | -84.14 Million USD | 98.353% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 9.752% |
| Genus plc | 6.4 Million USD | 121.66% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 114.229% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -48.839% |
| Marizyme, Inc. | -34.08 Million USD | 95.933% |
| ContraFect Corporation | -56.88 Million USD | 97.563% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 83.398% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 69.564% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 1.122% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 51.368% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 49.606% |
| MultiCell Technologies, Inc. | -722.81 USD | -191686.915% |
| Accustem Sciences Inc. | -3.74 Million USD | 62.998% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.65% |
| EV Biologics, Inc. | -483.06 Thousand USD | -186.972% |
| Q BioMed Inc. | -3.44 Million USD | 59.768% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 139.16% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -255.842% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 47.241% |
| Biomind Labs Inc. | -1 Million USD | -37.307% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 71.59% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 79.148% |
| Skye Bioscience, Inc. | -13.67 Million USD | 89.86% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 30.215% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4528.255% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 72.519% |
| IMV Inc. | -38.67 Million USD | 96.415% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.265% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 28.27% |
| GB Sciences, Inc. | -1.42 Million USD | 2.411% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.717% |
| HST Global, Inc. | -140.9 Thousand USD | -883.808% |
| CSL Limited | 3.7 Billion USD | 100.037% |
| Halberd Corporation | -75.05 Thousand USD | -1747.109% |
| Enzolytics Inc. | -2.14 Million USD | 35.487% |
| Resverlogix Corp. | -12.74 Million USD | 89.127% |
| Affymax, Inc. | -15.04 Million USD | 90.787% |
| SYBLEU INC | -149.18 Thousand USD | -829.25% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 56.246% |
| argenx SE | -425.04 Million USD | 99.674% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.503% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -32.783% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 12.227% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 59.287% |
| AVAX Technologies, Inc. | 6.69 Million USD | 120.712% |
| Zenith Capital Corp. | -8.94 Million USD | 84.499% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.667% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7857.379% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 43.541% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -708.267% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.478% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 52.219% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -40.872% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 25.645% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -10.371% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 30.852% |
| BioStem Technologies, Inc. | -7.77 Million USD | 82.179% |
| ONE Bio Corp. | 13.68 Million USD | 110.132% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -663.84% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -3.806% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -23.233% |
| Agentix Corp. | -1.37 Million USD | -1.057% |
| LadRx Corporation | -3.82 Million USD | 63.745% |
| Cell Source, Inc. | -4.32 Million USD | 67.95% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -233.652% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -101.799% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -101.799% |
| NovAccess Global Inc. | -2.46 Million USD | 43.803% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 52.516% |
| Itoco Inc. | -919.14 Thousand USD | -50.821% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 67.293% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -23.883% |
| Kadimastem Ltd | -3.04 Million USD | 54.403% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -429.659% |
| CytoDyn Inc. | -18.05 Million USD | 92.323% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5407.569% |
| Mobile Lads Corp. | -554.55 Thousand USD | -149.978% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -529.893% |
| Qrons Inc. | -643.67 Thousand USD | -115.365% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -145.475% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 37.833% |
| Rebus Holdings, Inc. | -664 Thousand USD | -108.773% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 23.678% |
| International Stem Cell Corporation | -663 Thousand USD | -109.088% |
| Bioxytran, Inc. | -3.82 Million USD | 63.712% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2533.463% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6715.413% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.178% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 14.323% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -88.392% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 55.44% |
| Neutra Corp. | -229.48 Thousand USD | -504.07% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 92.096% |
| PureTech Health plc | -146.19 Million USD | 99.052% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.55% |
| IXICO plc | -1.43 Million USD | 3.531% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 85.394% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.862% |
| CSL Limited | 3.81 Billion USD | 100.036% |
| Cellectis S.A. | -108.85 Million USD | 98.727% |